Investors

Corporate News & Publications

CLINUVEL's company releases, including archives.

Preliminary results of Singaporean Phase II study CUV103 in patients with naturally darker skin are consistent with results from the previous US Phase II trial (CUV102) EXECUTIVE SUMMARY PRELIMINARY RESULTS CUV103 · Positive pigmentary response to SCENESSE® in combination with narrowband ultraviolet B (NB-UVB) in patients of darker skin complexion · Combination therapy appears safe and effective · Physicians’ and patients’ assessment of SCENESSE® is positive Melbourne, Australia and Leatherhead, UK, December 3, 2015 Clinuvel Pharmaceuticals Ltd (ASX: CUV; XETRA-DAX: UR9; ADR: CLVLY) today announced positive preliminary results from a Singaporean Phase II trial (CUV103) evaluating its drug SCENESSE® (afamelanotide…
Tuesday, 24 November 2015 13:09

Results of Meeting

Tuesday, 24 November 2015 13:08

CEO's AGM Presentation

Tuesday, 24 November 2015 13:07

Chair’s Address to the Annual General Meeting

Wednesday, 04 November 2015 17:58

Form 604 - November 4, 2015

Friday, 30 October 2015 18:22

Appendix 4C - Q1 FY16

Friday, 23 October 2015 16:43

Notice of Annual General Meeting/Proxy Form

Friday, 23 October 2015 09:01

Appendix 4G

Thursday, 22 October 2015 14:57

Annual Report for the year ended 30 June 2015

CLINUVEL's Annual Report for the year ended 30 June 2015.
Wednesday, 07 October 2015 17:04

Form 604 - October 7, 2015

Quick Links